 BidaskClub cut shares of Dicerna Pharmaceuticals NASDAQ:DRNA from a buy rating to a hold rating in a report issued on Wednesday morning, BidAskClub reports. DRNA has been the subject of a number of other research reports. Berenberg Bank started coverage on Dicerna Pharmaceuticals in a research report on Thursday, March 19th. They set a buy ... 